A Real World Study of Ensartinib in Advanced ALK-positive NSCLC

Clinical trial NCT05498064 · RECRUITING

Trial details

NCT number: NCT05498064
Sponsor: Peking Union Medical College Hospital
Status: RECRUITING
Study type: OBSERVATIONAL

Carcinoma, Non-Small-Cell Lung Anaplastic Lymphoma Kinase I1171N Ensartinib

Start date: 2022-05-13
Primary completion: 2025-12-31
Enrollment: 490

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.